SYRS vs. CUE, PGNX, IGMS, CDMO, OLMA, TVTX, CMPS, HRTX, ALT, and ATXS
Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Cue Biopharma (CUE), Progenics Pharmaceuticals (PGNX), IGM Biosciences (IGMS), Avid Bioservices (CDMO), Olema Pharmaceuticals (OLMA), Travere Therapeutics (TVTX), COMPASS Pathways (CMPS), Heron Therapeutics (HRTX), Altimmune (ALT), and Astria Therapeutics (ATXS). These companies are all part of the "medical" sector.
Syros Pharmaceuticals (NASDAQ:SYRS) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.
In the previous week, Cue Biopharma had 1 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 3 mentions for Cue Biopharma and 2 mentions for Syros Pharmaceuticals. Syros Pharmaceuticals' average media sentiment score of 1.44 beat Cue Biopharma's score of 1.43 indicating that Syros Pharmaceuticals is being referred to more favorably in the media.
91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Comparatively, 7.5% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Syros Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.
Syros Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 174.51%. Cue Biopharma has a consensus price target of $8.00, indicating a potential upside of 390.80%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Syros Pharmaceuticals.
Cue Biopharma has lower revenue, but higher earnings than Syros Pharmaceuticals. Cue Biopharma is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Syros Pharmaceuticals received 218 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 63.89% of users gave Syros Pharmaceuticals an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
Cue Biopharma has a net margin of -711.84% compared to Syros Pharmaceuticals' net margin of -1,656.34%. Cue Biopharma's return on equity of -128.30% beat Syros Pharmaceuticals' return on equity.
Summary
Cue Biopharma beats Syros Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Syros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syros Pharmaceuticals Competitors List
Related Companies and Tools
